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treatment. Addressing these problems is essential to improve the quality of life of 
young women with breast cancer.
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Objectives: The purpose of this study is to describe pharmacists’ personal skin 
cancer prevention strategies and to determine if there were differences based on 
age and gender. MethOds: Pharmacists registered and living in Arizona with an 
email address with the State Board of Pharmacy were eligible for the study. A ques-
tionnaire was developed based on questions from the National Health Iinterview 
Survey. The questionnaire included preventive strategies, knowledge, clinical out-
comes, and demographic questions. The questionnaire was administered by using 
an electronic, on-line survey form. Two emails with a link to the questionnaire site 
were used to recruit participants. Prevention strategies assessed included the use 
of sunscreen, protective clothing (wearing a hat, a cap, long-sleeved shirt or pants), 
or seeking shade. Results: A total of 261 pharmacists responded; their average age 
was 44.9(SD = 13.7) and there were 167 women and 94 men. Men and women used a 
similar number of strategies (mean = 2.0, SD = 1.3; mean = 1.9, SD = 1.1, respectively; 
p = 0.058), however, the types of strategies used differed. Men were more likely to 
wear a baseball cap (p< 0.001) and a long sleeved shirt(p= 0.018). Women were more 
likely to use sunscreen(p= 0.001). Older pharmacists(> 40) were more likely to wear a 
hat than younger pharmacists (p< 0.001). Clinical outcomes did not differ by gender 
but did differ by age. Older pharmacists were more likely to have had a sunburn 
with blisters than younger pharmacists(p= 0.004) and older pharmacists were more 
likely to report a diagnosis of a precancerous skin lesion (p< 0.001) or a diagnosis of 
skin cancer(p = 0.004). cOnclusiOns: Men and women pharmacists used a similar 
number of skin cancer prevention strategies but women were more likely to use 
sunscreens. Older pharmacists were more likely to use protective clothing and to 
report a diagnosis of skin cancer.
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Objectives: An estimated 70% of the Brazilian population is covered exclusively by 
the public healthcare system; consequently, many patients with cancer must rely 
on few public institutions for oncology care. This study investigated the impact of 
insurance type on access, health-related quality of life (HRQoL), mood and sleep 
related outcomes for real-world cancer patients in Brazil. MethOds: Data came 
from the 2011 (n= 12,000), 2012 (n= 12,000), & 2014 (n= 9,082) Brazil National Health 
and Wellness Survey, an internet-based general health survey representative of the 
general population in age and gender. Among 33,082 respondents, 1,019 reported a 
cancer diagnosis. Respondents were categorized into public insurance (n= 405) or 
private insurance (n= 614). Initial analyses used one-way ANOVAs and chi-squares, 
and generalized linear models were used to control for demographic and health 
characteristics (e.g., income) to isolate differences in HRQoL, mood and sleep dis-
orders, and healthcare resource use according to insurance type. Results: Those 
with private insurance were more likely to be white (76.9%), have completed their 
degree (57.5%), have annual household income ≥ R$6501 (49.8%), be obese (23.9%), 
and drink alcohol (69.4%). Those on private insurance were also more likely to report 
having generalized anxiety disorder (9.0% vs. 4.7%) and overall sleep issues (50.2% 
vs. 43.5%) than those on public insurance. After controlling for covariates, those with 
private insurance reported a higher mean number of doctor visits (9.87 vs. 6.58), 
emergency room visits (1.05 vs. 0.57), and hospitalizations (0.54 vs. 0.32). There were 
no differences on HRQoL. cOnclusiOns: Lower resource use among those on the 
public system indicates disparities in healthcare access among cancer patients in 
Brazil. HRQoL was not associated with insurance type, while mood and sleeping 
disorders were more common among those with private insurance. Further research 
is needed to understand why inequality of access is not reflected in HRQoL decre-
ments in this population.
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Objectives: Treatment for Non-Hodgkin’s Lymphoma (NHL) is highly depend-
ent on the subtype of NHL. Indolent Lymphomas (Follicular Lymphoma (FL), 
Waldenstrom’s Macroglobulena (WM)) are slow-growing and are generally only 
treated once the patient becomes symptomatic. Aggressive lymphomas (Diffuse 
Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL)) have a poor prog-
nosis, and treatment is expected to start at diagnosis. The objective is to quantify 
the distribution of NHL subtypes and then compare drug treatment practices across 
each subtype. MethOds: The study used ONCO-CAPPS, a proprietary database of 
patient chart abstractions collected through regular surveys of physician panels. 
The data includes demographic details, disease markers, and a summary of the 
patients’ cancer treatments from the time of diagnosis. Data were collected each 
quarter in 2014 and used to categorize patients with NHL based on subtype and 
document their sequence of treatments. Results: Out of all NHL patients being 
treated, 45% had FL, 33% had DLBCL, 7% had MCL and 4% had WM. The remaining 
11% had other forms of NHL. The proportion of NHL patients with FL was found to 
CaNCer – Patient-reported outcomes & Patient Preference studies
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Objectives: evaluate the relationship between the non compliance to the claim 
of medication and incidence of hospitalization in patients with breast cancer in 
oral antineoplastic therapy. MethOds: case-control study in patients with breast 
cancer, that claimed their medicines in pharmacies between january of 2012 and 
December 2014. Was defined as a case patients that during the observation period 
claimed their drugs in pharmacy < 95% of the time. The sample size was calcu-
lated for a proportion of cases exposed 40% an OR of 3.7, a relation case-control 
1:2, a 95% confidence and an potency 80%. The final sample was composed of 40 
cases and 80 controls (randomly selected from the same cases population). For 
univariate analysis was used absolute and relative frequencies and summary 
measures. For binary analysis contingency tables, chi-square tests. The statistical 
measure of force used was the Odds Ratio. Results: the proportion of hospital-
ized patients who did not comply with the claim of medicines in pharmacy was 
45.7% (p:0.06). The non adherent patients were hospitalized 2.14 times more than 
compliant patients, (OR 2.14 [IC95% 0.94-4.8]). If we avoided the non compliance 
claim of medications in pharmacies, we would avoid 24% of hospitalizations (FA 
24% [IC95% 5.4%-5.7%]). cOnclusiOns: the non compliance to claim medication 
in pharmacy is a influence factor increased in the incidence of hospitalization in 
breast cáncer patients.
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Objectives: New treatments in prostate cancer intend to have more precise tech-
niques to reduce side effects and improve quality of life. The aim of this study was 
to estimate health related quality of life of patients with localized prostate cancer 
undergoing robot-assisted laparoscopic prostatectomy or conventional open pros-
tatectomy. MethOds: Prospective cohort study was conducted from March 2014 to 
January 2015. All patients that were diagnosed with localized prostate cancer answer 
the EQ -5D 3L and then went to robot-assisted laparoscopic prostatectomy or conven-
tional open prostatectomy as recommended by their doctor. They also answered the 
questionnaire at hospital discharge and at six month follow-up using, in a reference 
cancer hospital in Rio de Janeiro. Results: Median age was 60.06 years, prostate spe-
cific antigen in the open surgery was 9.25±4.59 ng/dl and 8.15±4.34 ng/dL in the robotic 
surgery, blood loss was higher in the open surgery. Among the 18 patients in the open 
surgery and the 27 in the robotic surgery the most significant result was the loss of 
quality of life in the group of open surgery at hospital discharge with less 10 points 
in the VAS and less 10.9% in utility (statistically and clinically significant) comparing 
to baseline. The difference between the two techniques is 11% when observed the 
loss in the VAS of the open surgery group and the gain in the robotic surgery. At six 
months the change in quality of life was not significant when compared to baseline, 
suggesting that this is not sustained over time. cOnclusiOns: This study helps 
in discussion about the benefits of robotic prostatectomy over the open procedure. 
Even with a significant difference between the two techniques in the immediate 
postoperative period favoring robotic surgery, this difference was not maintained at 
six months, which may not justify the higher costs of this procedure.
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Objectives: The purpose of this study was to determine the frequency of body 
image and sexual problems after 12 month of follow up among women diagnosed 
with breast cancer at age 35 or younger. Types of breast cancer treatment effect 
physical appearance as loss of the body part, disfigurement, scars or skin changes. 
The goal of this paper is to comprehend the body image and sexual distress of newly 
diagnosed younger survivors. MethOds: A multi-ethnic population-based sample 
of 72 out of 124 women aged 21–35 who were married or in a stable unmarried 
relationship were interviewed with in situ, or regional breast cancer. The women 
participating in this study were underwent treatment from 2003 to 2013 at 2 differ-
ent hospitals located in south India. Results: Body image and sexual problems 
were experienced by a substantial proportion of women after diagnosis or treat-
ment. Different type of treatment patterns were used as 59 (81.94%) women under-
went surgery, 39 (54.1%) were treated with CMF chemotherapy, 54 (72.2%) women 
underwent hormonal therapy and remaining with radiotherapy. The Hopwood Body 
Image Scale was used for the assessment of the body image perception which 
shown less physically attraction in most of the patients with self-consciousness, 
seeing themselves naked in mirror and dissatisfied with scars on their body. The 
Female Sexual Distress Scale (FSDS) was used to assess the sexual distress in women 
with breast cancer. The mean score was 24.4 (47%) which relatively shows higher 
sexual distress with the major sexual problem; distress about sex life, Frustration 
by the sexual problems, Dissatisfaction with sex life and inferiority because of 
sexual problem among the women. cOnclusiOns: Difficulties related to body 
image and sexuality were common and occurred soon after surgical and adjuvant 
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oncologic products within Latin America (LA) in comparison to a developed market 
(Canada). MethOds: A panel of opinion leaders and policy-makers from Brazil, 
Colombia, Argentina, Mexico, and Canada was convened to understand current 
challenges in health care, patient access, and reimbursement of high-cost onco-
logic products with a focus on NSCLC. Results: In LA, patient access to biomarker 
testing in all cancers is limited, except for common biomarkers like HER2 in breast 
cancer. In Canada, there is no uniform coverage across provinces for diagnostic 
testing. In LA, there is an inconsistent and varied level of prioritization in public 
and private markets amongst various cancers (e.g. breast) for which access to high-
cost oncologic agents is more likely. Specifically, NSCLC is not prioritized because 
of its perceived association with smoking and “poor prognosis”. It is unlikely in LA 
for expensive medications to be included in the standard benefit packages, and 
the review process can be lengthy for those that are included. Some patients may 
get access to some medications through filing a judicial claim against the govern-
ment for individual drug cost reimbursement. Although various LA countries are 
witnessing evolution in some form, unlike in Canada, HTA does not have a substan-
tial influence on payer decision-making on drug coverage. There was a consensus 
for enrolling more patients in clinical trials, development of regional/local clinical 
guidelines, and generating real-world and cost-effectiveness evidence to potentially 
improve reimbursement and shorten time to access to medications. cOnclusiOns: 
Access to high-cost oncologic medications could be potentially improved through 
increased patient participation in clinical trials, generation of relevant guidelines 
and robust cost-effectiveness and evidence-based analyses, and implementation 
of risk-sharing agreements requiring innovative cancer care models.
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ObjectivOs: Estimar la utilización de servicios de salud para el tratamiento del 
cáncer de pulmón en centros especializados. MetOdOlOgíAs: Se realizó un estudio 
retrospectivo, con una muestra representativa de 100 historias clínicas de pacientes 
con ingreso por cáncer de pulmón en 2013 en tres hospitales. Se elaboró una base 
de datos con el registro de utilización de servicios antes del ingreso y durante el 
tratamiento en el hospital. ResultAdOs: La edad promedio al ingreso fue 43 años. 
El 35% de los pacientes eran hombres, y el 65% eran mujeres. El 74% eran fumadores. 
Antes del ingreso, 11% de los pacientes recibió radioterapia, 9% quimioterapia y en el 
15% se realizó cirugía. El marcador tumoral EGFR fue reportado en una historia. En 
el 61% de las notas de ingreso, se indicó el resultado de la biopsia. Luego del ingreso, 
el peso del paciente fue reportado en el 41% de las historias, la talla en el 66%. En 
el 33% de las historias se registró el estadio del cáncer en la primera consulta. El 
promedio de consultas por paciente fue 6. El 2% de los pacientes requirió ingresos 
por emergencia. El 18% de los pacientes fue hospitalizado en el período de reporte. 
El marcador tumoral EGFR se reportó en 11% de las historias, en 38% los valores de 
LDH. En el período analizado, el 53% de los pacientes recibió quimioterapia y el 10% 
radioterapia. cOnclusiOnes: De acuerdo con cifras oficiales, el cáncer de pulmón 
representó en 2012 el 14,83% de la mortalidad en Venezuela. El trabajo constituye 
el primero en la literatura venezolana para la estimación de servicios utilizados en 
el tratamiento respectivo. Los resultados son un aporte para la determinación de 
los costos involucrados, así como para la revisión de los estándares de atención en 
los servicios de salud.
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ObjectivOs: Estimar la utilización de servicios de salud para el tratamiento del 
cáncer de estómago en centros especializados. MetOdOlOgíAs: Se realizó un 
estudio retrospectivo, con una muestra representativa de 100 historias clínicas 
de pacientes con ingreso por cáncer de estómago en 2013 en tres hospitales. Se 
elaboró una base de datos con el registro de utilización de servicios antes del 
ingreso y durante el tratamiento en el hospital. ResultAdOs: La edad promedio 
al ingreso fue 48 años. El 51% de los pacientes eran hombres, y el 49% eran mujeres. 
Antes del ingreso al servicio de oncología, 3% de los pacientes recibió radiotera-
pia, 5% quimioterapia y en el 52% de los casos se realizó cirugía. No se registró la 
realización de marcadores tumorales (ALK, EGFR, BRAF, y PDL1). En el 64% de las 
notas de ingreso, se indicó el resultado de la biopsia. Luego del ingreso, el peso y 
la talla fueron reportados en el 67% de las historias. En el 28% de las historias se 
registró el estadio del cáncer en la primera consulta. El promedio de consultas 
por paciente fue 4. En el período analizado, el 32% de los pacientes fue hospitali-
zado, el 30% recibió quimioterapia y el 6% radioterapia. El 7% de los pacientes 
requirió ingresos por emergencia. No se reportaron marcadores tumorales durante 
el tratamiento en el hospital. En 32% de las historias se indicaron los valores de 
LDH. cOnclusiOnes: De acuerdo con cifras oficiales, el cáncer de estómago rep-
resentó en 2012 el 16,64% de la mortalidad en Venezuela. El trabajo constituye el 
primero en la literatura venezolana para la estimación de servicios utilizados en 
el tratamiento respectivo. Los resultados son un aporte para la determinación de 
los costos involucrados, así como para la revisión de los estándares de atención 
en los servicios de salud.
be higher than the proportion expected by incidence statistics; this may be due to 
the indolent nature of FL and correspondingly high survival. FL was predominantly 
treated with Benda/Ritux and CVP R with some patients receiving CHOP R. WM was 
treated with CVP R, Benda/Ritux and Bort/Dexam +/- Ritux. MCL was treated with 
Benda/Ritux, Stem Cell Transplant, and CHOP R. DLBCL was treated with CHOP R. 
The other forms of NHL had various treatment regimens. cOnclusiOns: The most 
prevalent NHL subtypes are FL and DLBCL. Treatment decisions for NHL are highly 
dependent on subtype, with indolent lymphomas being treated with regimens that 
are easier to tolerate, and aggressive lymphomas being treated predominately with 
CHOP R, an aggressive regimen that is hard to tolerate.
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Objectives: Treatment of metastatic pancreatic cancer (MPC) remains a challenge 
for oncologists worldwide, since not many innovations were added lately. From 
1997 to 2011 (when the pivotal study on FOLFIRINOX was published), patients were 
essentially treated with gemcitabine. Recent publications show new options, such 
as OFF regimen. Nevertheless, there is a lack real world data showing how patients 
are actually treated. Our aim is to understand the treatment patterns for MPC in 
Brazil. MethOds: MPC patients receiving any line of treatment during 2014 were 
eligible and selected from Evidências-Kantar Health administrative claims database 
(comprising 4 million lives insured by 46 different private health insurance com-
panies). After patient de-identification, data on treatments, number of cycles and 
demographics, were collected. The most reported treatments according to generic 
name were defined as patterns of care. Results: Sixty-three patients with MPC 
were identified at the database, 53 in first and 10 in second line treatment. Patient 
baseline characteristics were: average age 63.5 years (40 to 84), 66.72 kilos (45 to 
126kg), 1.65 meters of height (1.46 to 1.82m), and 1.71m2 body surface area (1.34 
to 2.3 m2). The most common regimen in first line was gemcitabine monotherapy 
(58.5%) followed by FOLFIRINOX (37.7%) and OFF (1.88%). In second line, OFF was 
the most prescribed regimen (80%), followed by gemcitabine monotherapy (10%) 
and FOLFORINOX (10%). Most patients in first-line received 3 cycles of treatment 
(43.4%), 32.1% received 6 cycles, 13,2% received 12 cycles and 11,3% received vari-
able length of treatment. Patients in second line received either 3 cycles (30%) or 
6 cycles (70%). cOnclusiOns: Despite the higher overall survival demonstrated 
by FOLFIRINOX study, the first option for first-line treatment of MPC patients is 
still gemcitabine. However, in second line the trend appears to be shifting towards 
OFF regimen.
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Objectives: There is limited data on the prevalence, rate of mutations, and pat-
terns of treatment in a “real-world” setting in Brazil. The aim of this retrospective 
observational study was to evaluate the above-mentioned aspects from the pri-
vate health system’s perspective in the country. MethOds: Data from 44 HMOs 
on all patients with metastatic NSCLC receiving any line of treatment between 
September 2013 - September 2014 using Evidências-Kantar Health private mar-
ket administrative claims database was analyzed. After patient de-identification, 
information on demographics, diagnosis, and treatment regimens and duration 
was collected. Prevalence of patients in each treatment line was calculated by the 
number of existing cases of a disease by the total population with lung cancer at one 
year. Results: We identified 273 lung cancer patients of which 182 patients (66.7%) 
had metastatic NSCLC, and were thus eligible for analysis. The most frequent histol-
ogy type was adenocarcinoma (71%) followed by squamous cell carcinoma (12%). 
The majority (81%) was not tested for any mutation. Among the tested patients 
(n= 35), 1 patient was ALK+ and 17 were EGFR+. The only ALK+ patient received a 
second line treatment with carboplatin+pemetrexed. Of the 17 patients with EGFR 
mutation, 52.9% used erlotinib and 23.5% gefitinib. Patient baseline characteristics 
of analyzed 182 patients were: average age of 64.3 years, 67.2 kilos, 1.6 m height, and 
1.74m2 body surface area. Nineteen treatment regimens were identified and most 
patients received 3 cycles of treatment. The most common regimens in first, second, 
and third-line treatments were carboplatin+pemetrexed (31%), docetaxel mono-
therapy (57.1%), and erlotinib (80%), respectively. The proportion of patients with 
NSCLC that undergo first, second, third, fourth, and fifth-line treatments in one year 
was 46.2/100, 20.5/100, 3.7/100, 0.7/100, and 1.1/100, respectively. cOnclusiOns: 
Mutation testing was very low, representing a significant unmet need, as patients 
with mutations may not be receiving appropriate targeted treatment in first-line.
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Objectives: To understand key market access issues pertaining to reimburse-
ment, HTA policies, guidelines, and ways to improve patient access for innovative 
